Vitrafy expands US blood partnerships and enters cell therapy market
VFY: $2.36 -2.07% · MC: $165M
Vitrafy added Versiti as its third US civilian blood partner and agreed to work with Charter Medical, extending its cryopreservation program into cell and gene therapy. Its partnerships now cover approximately 17% of US civilian blood collection sites, while partner device deployments are planned for the current quarter and US medical device listing remains on track for late 2026. The company ended the quarter with A$38 million in cash and term deposits.

Comments